Abstract
There has been a significant increase in the number of cytokines known to exist, over the past few years. This has led to a re-examination of the established roles of cytokines, as the functions of newly identified members are characterized. In this review, we describe how the recent discovery and characterization of interleukin (IL) -23 has led to a re-evaluation of the role of interferon (IFN) γ and IFNγ-inducing factors in experimental autoimmune encephalomyelitis (EAE). Recent studies suggest that IFNg-secreting T cells, considered the hallmark of EAE, may not be the major detrimental effector cell, and may even have a regulatory function. The impact of this on current understanding of cytokine networks underlying CNS inflammation in EAE is discussed.
Keywords: interferon gamma, interleukin 23, experimental autoimmune encephalomyelitis
Current Pharmaceutical Design
Title: The Changing Face of Cytokines in the Brain: Perspectives From EAE
Volume: 11 Issue: 8
Author(s): R. D. Wheeler and T. Owens
Affiliation:
Keywords: interferon gamma, interleukin 23, experimental autoimmune encephalomyelitis
Abstract: There has been a significant increase in the number of cytokines known to exist, over the past few years. This has led to a re-examination of the established roles of cytokines, as the functions of newly identified members are characterized. In this review, we describe how the recent discovery and characterization of interleukin (IL) -23 has led to a re-evaluation of the role of interferon (IFN) γ and IFNγ-inducing factors in experimental autoimmune encephalomyelitis (EAE). Recent studies suggest that IFNg-secreting T cells, considered the hallmark of EAE, may not be the major detrimental effector cell, and may even have a regulatory function. The impact of this on current understanding of cytokine networks underlying CNS inflammation in EAE is discussed.
Export Options
About this article
Cite this article as:
Wheeler D. R. and Owens T., The Changing Face of Cytokines in the Brain: Perspectives From EAE, Current Pharmaceutical Design 2005; 11 (8) . https://dx.doi.org/10.2174/1381612053381657
DOI https://dx.doi.org/10.2174/1381612053381657 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
New Insights into Vitamin D and Autophagy in Inflammatory Bowel Diseases
Current Medicinal Chemistry The Inhibitory Effect of Cyclosporine A and Prednisolone on Both Cytotoxic CD8+ T Cells and CD4+CD25+ Regulatory T Cells
Current Signal Transduction Therapy Immunological Mechanisms of Neuropsychiatric Lupus
Current Immunology Reviews (Discontinued) Multiple Sclerosis – Established and Novel Therapeutic Approaches
Central Nervous System Agents in Medicinal Chemistry Medicinal Chemistry of Ureido Derivatives as Anti-Infectives
Anti-Infective Agents in Medicinal Chemistry Tryptophan Catabolism in IDO+ Plasmacytoid Dendritic Cells
Current Drug Metabolism Systemic Immunomodulation of Autoimmune Disease Using MHC-Derived Recombinant TCR Ligands
Current Drug Targets - Inflammation & Allergy Preclinical Models of Multiple Sclerosis: Advantages and Limitations Towards Better Therapies
Current Medicinal Chemistry Applications of Umbilical Cord Derived Mesenchymal Stem Cells in Autoimmune and Immunological Disorders: From Literature to Clinical Practice
Current Stem Cell Research & Therapy Experimental and Clinical Application of Plasmid DNA in the Field of Central Nervous Diseases
Current Gene Therapy Potential Application of Gene Therapy to X-Linked Agammaglobulinemia
Current Gene Therapy The Role of P-Glycoprotein in Psychiatric Disorders: A Reliable Guard of the Brain?
Central Nervous System Agents in Medicinal Chemistry Idiopathic Transverse Myelitis and Neuromyelitis Optica: Clinical Profiles,Pathophysiology and Therapeutic Choices
Current Neuropharmacology Prostaglandins and Cyclooxygenases in Glial Cells During Brain Inflammation
Current Drug Targets - Inflammation & Allergy Transient Focal Lesions in the Splenium of the Corpus Callosum with Restricted Diffusion: An Enigma
Current Medical Imaging How to Get from Here to There: Macrophage Recruitment in Alzheimers Disease
Current Alzheimer Research Roles of Secreted Phospholipases A<sub>2</sub> in the Mammalian Immune System
Protein & Peptide Letters Editorial: [Hot Topic: Central Nervous System Drugs in the Treatment of Neurological Disorders]
Central Nervous System Agents in Medicinal Chemistry Targeting Vascular Changes in Lesions in Multiple Sclerosis and Experimental Autoimmune Encephalomyelitis
Central Nervous System Agents in Medicinal Chemistry Recent Advances in Regulatory T Cell Therapy of Autoimmunity, Graft Rejection and Cancer
Recent Patents on Inflammation & Allergy Drug Discovery